Effect of HLA restriction on racial and ethnic disparities in access to immune therapies for advanced synovial sarcoma
Engineered T-cells targeting MAGE-A4 have shown encouraging safety and efficacy in advanced SS; however, eligibility restrictions will lead to racial and ethnic disparities. HLA-independent solutions must be developed to counter disparities and ensure all patients have access.
Authors
- Michael J. Wagner (ORCID: https://orcid.org/0000-0002-8812-1653)
- Vinayak Venkataraman (ORCID: https://orcid.org/0000-0003-0941-2354)
- David S. Shulman (ORCID: https://orcid.org/0000-0002-5994-2604)
- Seth M. Pollack (ORCID: https://orcid.org/0000-0002-2466-0607)
- Kelly G. Paulson (ORCID: https://orcid.org/0000-0002-0033-3708)
- Hannah R. Abrams (ORCID: https://orcid.org/0000-0003-1044-7757)
- Elizabeth T. Loggers (ORCID: https://orcid.org/0000-0003-3432-0443)
Institutions
- Northwestern University (US)
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Harvard University (US)
- Fred Hutch Cancer Center (US)
- Swedish Medical Center (US)
- Swedish Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/oncolo/oyaf193
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00